Symbols

BRNS

Barinthus·NASDAQ

--(--)

BRNS Profile

Barinthus Biotherapeutics Plc

A clinical-stage biopharmaceutical company that develops immunotherapeutcs & vaccines for infectious diseases & cancer

Industry

Biological Technology

Established Date

Listing Date

04/30/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.barinthusbio.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

20400 Century Blvd, Suite 210, Germantown, MD 20874

Business

Introduction

Barinthus Biotherapeutics plc is a public limited company incorporated under the laws of England and Wales in March 2021. The company is a clinical-stage biopharmaceutical company focused on the development of novel immunotherapy candidates for autoimmune and inflammatory diseases. Its lead drug candidate, VTP-1000, utilizes its proprietary SNAP-TI platform to promote immune tolerance in celiac disease, while VTP-300 utilizes viral vector technology to target chronic hepatitis B.